Skip to main content
. 2022 May 13;6(10):2967–2976. doi: 10.1182/bloodadvances.2021006484

Table 2.

Events and 6-month cumulative incidences of incident VTE in patients with cancer initiating chemotherapy

Patients, n Events, n Cumulative incidence, % (95% CI)*
Overall 40 218 1 000 2.5 (2.3-2.6)
Khorana risk category
 0: low risk 14 250 210 1.5 (1.3-1.7)
 1-2: intermediate risk 21 565 610 2.8 (2.6-3.1)
 ≥3: high risk 4 403 180 4.1 (3.5-4.7)
Khorana score level
 1 12 856 318 2.5 (2.2-2.8)
 2 8 709 291 3.3 (3.0-3.7)
 3 3 623 141 3.9 (3.3-4.6)
 4 717 34 4.7 (3.4-6.5)
 5-6 63 5 7.9 (2.9-16.2)
Guideline threshold
 Score 0-1 27 106 529 2.0 (1.8-2.1)
 Score ≥2 13 112 471 3.6 (3.3-3.9)
*

Based on the cumulative incidence function considering death as competing risk.